Measurement of calorific content in a matter of minutes

The AC600 calorimeter from Leco uses rapid thermodynamics to analyze calorific content in five minutes.

Platelet analysis in whole blood

The new Multiplate analyzer from Triolab uses impedance aggregometry to measure the effects of platelet inhibitors on whole blood.

Microwave reactor for use in various synthesis applications

The Monowave 300 microwave reactor offers 850 watts of power for a variety of synthesis applications.

Double the channels for half the work

The 16-well pipettes from Capp cause less strain for the user when setting up a 384-well plate.

Higher performance UV-Vis spectrophotometry with double beams

The Biochrom Libra series of UV-Vis spectrophotometers now features double beams and variable bandwidths.

Density meters with six-digit precision

The new instruments from Krüss Optronic offer high sensitivity for density measurements.

Next generation sequencer in an accessible format

The GS Junior System is a new benchtop-sized next generation sequencing platform.

Your partnering tool - step by step

Profile, agenda and requests. Those are the basic steps to follow to use the partnering tool for Biotech Forum. Follow our guide to successful partnering!

Academia - a strong player on the lab market

While the industry was short of money during the financial crisis, government incentives were in full swing in Sweden during 2009. - Our sales to academia increased ten percent last year, says Håkan Hjortsmark, sales manager at Perkin Elmer.

9 steps to perfect partnering

Rigorous planning and a focus on your business plan is essential for successful partnering, accoring to Camilla Huse Bondeson at Conlega. Follow her 9 steps to perfect partnering.

High hopes for future partnering - the solution for struggling fairs

Business fairs are struggling but the concept of partnering is hotter than ever. By using social media, participants can prepare themselves for the perfect meeting.

International models among science parks

Science parks have become a part of modern communities. With science parks in Oxford, Cambridge and Nice setting good examples, a special potential emerged. Countries with a clear research goal are investing in new parks, and in China, the number is growing exponentially.

Early stage research and low turnaround dominates

Nordic science parks are full of advanced research performed by small companies but little research is done in later stages. Only a couple of the best performers have companies in phase III, according to Biotech Scandinavia's survey.

Ideon - Sweden's oldest science park

Old is not synonymous with boring. Swedens oldest science park Ideon still manages to attract young companies with big ideas. The recipe for success? To continue to invest in further development.

We are poor lobbyists

I doubt there has ever been a really well thought out Scandinavian campaign with intentions to really change attitudes among both the public and politicians.

Bengt Ågerup lämnar Q-Med

- Jag ser fram emot att bli pensionär ja, fast när jag säger det så skrattar alla, säger Bengt Ågerup. (Uppdaterad)

Kolnanorör bryts ner med enzym

Ett genombrott i forskningen kring kolnanorör öppnar för medicinsk användning av materialen.

Strålning vid cancer ökar hjärtrisk

Ny forskning från Karolinska Institutet visar att strålbehandling hos cancerpatienter verkar ge ökad risk för hjärt- och kärlsjukdom.

Astrapreparat bra vid by-pass

En klinisk studie från Uppsala Clinical Research Centre visar fördelar med Astras preparat jämfört med standardbehandlingen.

Förfalskning drabbar Q-Med

Förfalskade kopior av ett av bolagets preparat säljs på internet och nu utreder FDA situationen. - Detta ligger utom vår kontroll, säger Q-Meds ekonomichef.

Icke-invasiv probe för processövervakning

I en serie av prober med fiberoptik finns nu FDR-805 på marknaden för utveckling och uppskalning av processer.

Samarbetsdags för Big Pharma

Patientkontakt via sociala medier, mobilstödd övervakning av dosering eller datastödd läkemedelsutveckling. Framtidens big pharma-bolag måste vidga vyerna och leverera hälsoresultat i stället för läkemedel, enligt Ernst&Youngs senaste rapport Progressions, Pharma 3.0.

Identitetskris i intresseorganisationer?

Enorma förväntningar på ESS

1,4 miljarder euro för att bygga anläggningen och en årlig kostnad på 100 miljoner euro. ESS är en enorm investering, som bara överträffas av förväntningarna på projektet. Kritikerna hävdar att ESS inte är vad det skandinaviska forskningssamhället verkligen behöver.